|
1
|
Adamson ED: Oncogenes in development.
Development. 99:449–471. 1987.
|
|
2
|
Grander D: How do mutated oncogenes and
tumor suppressor genes cause cancer? Med Oncol. 15:20–26. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thomas RK, Baker AC, Debiasi RM, Winckler
W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L,
et al: High-throughput oncogene mutation profiling in human cancer.
Nat Genet. 39:347–351. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yarden Y: The EGFR family and its ligands
in human cancer. signalling mechanisms and therapeutic
opportunities. Eur J Cancer. 37:S3–S8. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Singh AB and Harris RC: Autocrine,
paracrine and juxtacrine signaling by EGFR ligands. Cell Signal.
17:1183–1193. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oliveira C, Velho S, Moutinho C, Ferreira
A, Preto A, Domingo E, Capelinha AF, Duval A, Hamelin R, Machado
JC, et al: KRAS and BRAF oncogenic mutations in MSS colorectal
carcinoma progression. Oncogene. 26:158–163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kumar R, Angelini S and Hemminki K:
Activating BRAF and N-Ras mutations in sporadic primary melanomas:
an inverse association with allelic loss on chromosome 9. Oncogene.
22:9217–9224. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shigematsu H and Gazdar AF: Somatic
mutations of epidermal growth factor receptor signaling pathway in
lung cancers. Int J Cancer. 118:257–262. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Solit DB, Garraway LA, Pratilas CA, Sawai
A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, et al: BRAF
mutation predicts sensitivity to MEK inhibition. Nature.
439:358–362. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Leboeuf R, Baumgartner JE, Benezra M,
Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA and Fagin
JA: BRAFV600E mutation is associated with preferential sensitivity
to mitogen-activated protein kinase kinase inhibition in thyroid
cancer cell lines. J Clin Endocrinol Metab. 93:2194–2201. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Davies BR, Logie A, McKay JS, Martin P,
Steele S, Jenkins R, Cockerill M, Cartlidge S and Smith PD: AZD6244
(ARRY-142886), a potent inhibitor of mitogen-activated protein
kinase/extracellular signal-regulated kinase kinase 1/2 kinases:
mechanism of action in vivo, pharmacokinetic/pharmacodynamic
relationship, and potential for combination in preclinical models.
Mol Cancer Ther. 6:2209–2219. 2007.
|
|
13
|
Pohl G, Ho CL, Kurman RJ, Bristow R, Wang
TL and Shih IeM: Inactivation of the mitogen-activated protein
kinase pathway as a potential target-based therapy in ovarian
serous tumors with KRAS or BRAF mutations. Cancer Res.
65:1994–2000. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dry JR, Pavey S, Pratilas CA, Harbron C,
Runswick S, Hodgson D, Chresta C, McCormack R, Byrne N, Cockerill
M, et al: Transcriptional pathway signatures predict MEK addiction
and response to selumetinib (AZD6244). Cancer Res. 70:2264–2273.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chung EJ, Brown AP, Asano H, Mandler M,
Burgan WE, Carter D, Camphausen K and Citrin D: In vitro and in
vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of
mitogen-activated protein kinase/extracellular signal-regulated
kinase 1/2 kinase. Clin Cancer Res. 15:3050–3057. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hagan M, Yacoub A and Dent P: Ionizing
radiation causes a dose-dependent release of transforming growth
factor alpha in vitro from irradiated xenografts and during
palliative treatment of hormone-refractory prostate carcinoma. Clin
Cancer Res. 10:5724–5731. 2004. View Article : Google Scholar
|
|
17
|
Dent P, Reardon DB, Park JS, Bowers G,
Logsdon C, Valerie K and Schmidt-Ullrich R: Radiation-induced
release of transforming growth factor alpha activates the epidermal
growth factor receptor and mitogen-activated protein kinase pathway
in carcinoma cells, leading to increased proliferation and
protection from radiation-induced cell death. Mol Biol Cell.
10:2493–2506. 1999.
|
|
18
|
Dent P, Yacoub A, Fisher PB, Hagan MP and
Grant S: MAPK pathways in radiation responses. Oncogene.
22:5885–5896. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cengel KA, Voong KR, Chandrasekaran S,
Maggiorella L, Brunner TB, Stanbridge E, Kao GD, McKenna WG and
Bernhard EJ: Oncogenic K-Ras signals through epidermal growth
factor receptor and wild-type H-Ras to promote radiation survival
in pancreatic and colorectal carcinoma cells. Neoplasia. 9:341–348.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Castedo M, Perfettini JL, Roumier T,
Andreau K, Medema R and Kroemer G: Cell death by mitotic
catastrophe: a molecular definition. Oncogene. 23:2825–2837. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Grana TM, Sartor CI and Cox AD: Epidermal
growth factor receptor autocrine signaling in RIE-1 cells
transformed by the Ras oncogene enhances radiation resistance.
Cancer Res. 63:7807–7814. 2003.PubMed/NCBI
|
|
22
|
Borrell-Pages M, Rojo F, Albanell J,
Baselga J and Arribas J: TACE is required for the activation of the
EGFR by TGF-alpha in tumors. EMBO J. 22:1114–1124. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee DC, Sunnarborg SW, Hinkle CL, Myers
TJ, Stevenson MY, Russell WE, Castner BJ, Gerhart MJ, Paxton RJ,
Black RA, et al: TACE/ADAM17 processing of EGFR ligands indicates a
role as a physiological convertase. Ann N Y Acad Sci. 995:22–38.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rousseau S, Papoutsopoulou M, Symons A,
Cook D, Lucocq JM, Prescott AR, O’Garra A, Ley SC and Cohen P:
TPL2-mediated activation of ERK1 and ERK2 regulates the processing
of pre-TNF alpha in LPS-stimulated macrophages. J Cell Sci.
121:149–154. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gomez MI, Seaghdha MO and Prince AS:
Staphylococcus aureus protein A activates TACE through
EGFR-dependent signaling. EMBO J. 26:701–709. 2007. View Article : Google Scholar
|
|
26
|
Otaki M, Hatano M, Kobayashi K, Ogasawara
T, Kuriyama T and Tokuhisa T: Cell cycle-dependent regulation of
TIAP/msurvivin expression. Biochim Biophys Acta. 1493:188–194.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Castedo M, Perfettini JL, Roumier T,
Yakushijin K, Horne D, Medema R and Kroemer G: The cell cycle
checkpoint kinase Chk2 is a negative regulator of mitotic
catastrophe. Oncogene. 23:4353–4361. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Valerie K and Povirk LF: Regulation and
mechanisms of mammalian double-strand break repair. Oncogene.
22:5792–5812. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ward JF, Joner EI and Blakely WF: Effects
of inhibitors of DNA strand break repair on HeLa cell
radiosensitivity. Cancer Res. 44:59–63. 1984.PubMed/NCBI
|
|
30
|
Toulany M, Dittmann K, Kruger M, Baumann M
and Rodemann HP: Radioresistance of K-Ras mutated human tumor cells
is mediated through EGFR-dependent activation of PI3K-AKT pathway.
Radiother Oncol. 76:143–150. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Martinez-Lacaci I, Kannan S, De Santis M,
Bianco C, Kim N, Wallace-Jones B, Ebert AD, Wechselberger C and
Salomon DS: RAS transformation causes sustained activation of
epidermal growth factor receptor and elevation of mitogen-activated
protein kinase in human mammary epithelial cells. Int J Cancer.
88:44–52. 2000. View Article : Google Scholar
|
|
32
|
Horne MM and Guadagno TM: A requirement
for MAP kinase in the assembly and maintenance of the mitotic
spindle. J Cell Biol. 161:1021–1028. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rainey MD, Black EJ, Zachos G and
Gillespie DA: Chk2 is required for optimal mitotic delay in
response to irradiation-induced DNA damage incurred in G2 phase.
Oncogene. 27:896–906. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lopergolo A, Tavecchio M, Lisanti S, Ghosh
JC, Dohi T, Faversani A, Vaira V, Bosari S, Tanigawa N, Delia D,
Kossenkov AV, Showe LC and Altieri DC: Chk2 phosphorylation of
survivin-DeltaEx3 contributes to a DNA damage-sensing checkpoint in
cancer. Cancer Res. 72:3251–3259. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ghosh JC, Dohi T, Raskett CM, Kowalik TF
and Altieri DC: Activated checkpoint kinase 2 provides a survival
signal for tumor cells. Cancer Res. 66:11576–11579. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shi X, Wang D, Ding K, Lu Z, Jin Y, Zhang
J and Pan J: GDP366, a novel small molecule dual inhibitor of
survivin and Op18, induces cell growth inhibition, cellular
senescence and mitotic catastrophe in human cancer cells. Cancer
Biol Ther. 9:640–650. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Asanuma H, Torigoe T, Kamiguchi K,
Hirohashi Y, Ohmura T, Hirata K, Sato M and Sato N: Survivin
expression is regulated by coexpression of human epidermal growth
factor receptor 2 and epidermal growth factor receptor via
phosphatidylinositol 3-kinase/AKT signaling pathway in breast
cancer cells. Cancer Res. 65:11018–11025. 2005. View Article : Google Scholar
|
